The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint.
Jönsson L, Wimo A, Handels R, Johansson G, Boada M, Engelborghs S, Frölich L, Jessen F, Kehoe PG, Kramberger M, de Mendonςa A, Ousset PJ, Scarmeas N, Visser PJ, Waldemar G, Winblad B.
Jönsson L, et al. Among authors: kehoe pg.
Lancet Reg Health Eur. 2023 May 22;29:100657. doi: 10.1016/j.lanepe.2023.100657. eCollection 2023 Jun.
Lancet Reg Health Eur. 2023.
PMID: 37251789
Free PMC article.
Review.